DFTX · Definium Therapeutics, Inc.
$37.40
-0.20 (-0.53%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$5.10B
Shares
134.37M
Volume · Oct 2
1.6M
Avg daily vol (3M)
2.14M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$37.40
Open$37.70
Day$36.86–38.14
52W close$10.68–48.45
Avg vol 30d2.2M
Short int11.8M · 8.8% float · 5.2d
Short vol53%
Last earningsAug 6, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
call held Jun 22, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$353.79M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.05B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+29.7%
Year over year · more shares
Price change (1Y)
+206.1%
Trailing year
Short interest
8.8%
Latest settlement · 5.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+36%
above
Price vs 50-day avg
−9%
below
RSI (14)
43
neutral
MACD trend
Positive
52-week position
71%
mid-range
Momentum
relative strength
1-month return
−2%
trailing
6-month return
+68%
trailing
YTD return
+179%
this year
Relative strength
+56%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $41 › 200d $27 — 50d above 200d
Institutional flow
Flat
1 of 369 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.77% of float · ▲ +19.8% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
369 holders — near 3-yr high, broad support
Squeeze score
66
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
79%
annualized · 1-yr
Max drawdown
−25%
past year
ATR
5.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+36%
Bullish
Price vs 50-day avg
−9%
Bearish
RSI (14)
43
Neutral
MACD trend
Positive
Bullish
52-week position
71%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $41 › 200d $27 — 50d above 200d
Institutional flow
Flat
1 of 369 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.77% of float · ▲ +19.8% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
369 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $11
Now $37 · 71%
Range high $48
vs 200-day avg +36%
vs 50-day avg -9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and investments | $1.1B | As of June 30, 2026 | — |
| DT120 GAD external research and development expenses | 22.65M | the three months ended June 30, 2026 filing | — |
| DT120 MDD external research and development expenses | 7.21M | the three months ended June 30, 2026 filing | — |
| DT120 other external research and development expenses | 3.7M | the three months ended June 30, 2026 filing | — |
| DT402 program external research and development expenses | 444K | the three months ended June 30, 2026 filing | — |
| Internal research and development costs | 13.41M | the three months ended June 30, 2026 filing | — |
| MADRS: LS mean change at Week 12 (DT120 ODT 100 µg) | -11 | the three months ended June 30, 2026 filing | — |
| MADRS: LS mean change at Week 12 (Placebo ODT) | -3.6 | the three months ended June 30, 2026 filing | — |
| MADRS: LS mean change at Week 6 (DT120 ODT 100 µg) | -13.3 | the three months ended June 30, 2026 filing | — |
| MADRS: LS mean change at Week 6 (Placebo ODT) | -5.2 | the three months ended June 30, 2026 filing | — |
| MADRS: remission rate (≤12) at Week 6 (DT120 ODT 100 µg) | 24% | the three months ended June 30, 2026 filing | — |
| MADRS: remission rate (≤12) at Week 6 (Placebo ODT) | 3% | the three months ended June 30, 2026 filing | — |
| MADRS: response rate (≥50%) at Week 6 (DT120 ODT 100 µg) | 35% | the three months ended June 30, 2026 filing | — |
| MADRS: response rate (≥50%) at Week 6 (Placebo ODT) | 7% | the three months ended June 30, 2026 filing | — |
| Preclinical and other programs external research and development expenses | 1.26M | the three months ended June 30, 2026 filing | — |
| Total DT120 program external research and development expenses | 33.56M | the three months ended June 30, 2026 filing | — |
| Total external research and development expenses | 35.26M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DFTX
this stock
Definium Therapeutics, Inc.
|
$5.10B | +179.3% | — | — | 8.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DFTX | +3.4% | -1.6% | +68.1% | -1.7% | +179.3% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +3.6% | -1.1% | +55.9% | -2.7% | +166.5% |